Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Genprex Inc. GNPX

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences

Posted on May 10, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will participate in a number of virtual conferences for the month of May, including the Diamond Equity … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio

Posted on May 6, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it has entered into an amendment to a May 2020 license agreement with a major cancer research center … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial

Posted on May 5, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Acclaim-2 Clinical Trial

Posted on May 4, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series

Posted on April 21, 2021 by MissionIR

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes

Posted on April 20, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers

Posted on April 12, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean

Posted on April 5, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the … Continue reading →

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21

Posted on March 30, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Spring 2021 Oncology Investor Conference

Posted on March 24, 2021 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 – April 2, … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment